Shionogi reorganizes US ops

Share this article:

Shionogi, the Japanese firm and developer of blockbuster cholesterol drug Crestor, has split US operations into two divisions, one focused on sales marketing and distribution, and the other on R&D and regulatory functions.

The latter office (Shionogi Inc.), located in New Jersey, will serve as the company's corporate headquarters and will oversee all US operations. The sales and marketing subsidiary, Shionogi Pharma, will remain in Atlanta.

Joseph Schepers, a spokesperson for the company, said the reorganization established one management team at the company, led by Sapan Shah, president and CEO of Shionogi Inc. Patrick Fourteau, previously CEO, president and director of Shionogi Pharma in Atlanta, has left the company, according to Schepers. Joseph Ciaffoni was promoted to president of Shionogi Pharma, and reports directly to Shah.

Fourteau was CEO of Sciele Pharma prior to Shionogi's acquisition of that company in October 2008. Sciele was fully integrated into the Shionogi organization this year, said Schepers.

According to Schepers, details about the number of jobs shifting from Atlanta to Shionogi's headquarters in New Jersey “haven't been finalized,” but all sales and marketing positions at the company “will remain in place,” he said.

In addition to Crestor, AstraZeneca's top-selling cholesterol drug, Shionogi also developed and manufactures doripenem, an injection for complicated intra-abdominal infection and urinary tract infection, marketed in the US by Ortho-McNeil-Janssen Pharmaceuticals, as Doribax.  

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...